Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Overview
Medtronic (MDT) is a global healthcare technology company renowned for its development and manufacture of innovative therapeutic medical devices. Operating across a broad spectrum of chronic and acute medical conditions, Medtronic delivers solutions that range from cardiac care to neuromodulation, spinal treatments, and diabetes management. Leveraging advanced technology in areas such as robotics, imaging, and artificial intelligence, the company is central in addressing some of the most challenging health problems of our time.
Core Business and Products
Medtronic’s operations are built on decades of experience in designing, manufacturing, and marketing a diverse portfolio of medical devices. Their offering includes therapeutic devices such as pacemakers, defibrillators, heart valves, and stents, as well as advanced surgical tools, spinal fixation devices, neurovascular products, and insulin pumps. Each product category is developed through a rigorous process that emphasizes quality, patient safety, and robust clinical evidence. The company’s products are engineered to meet the demanding needs of healthcare institutions and professionals in both domestic and international markets.
Technological Innovation
At the core of Medtronic’s success is its commitment to technological innovation. The company integrates advanced systems in medical robotics, data analytics, and state-of-the-art imaging to enhance procedural accuracy. For instance, its ecosystem that connects navigation, robotics, and data analytics exemplifies how integrated solutions can lead to more predictable outcomes in complex procedures. Medtronic has also embraced adaptive technology in neuromodulation, shown by its work in adaptive deep brain stimulation, which personalizes therapy based on real-time neural signals.
Global Market Position and Operational Excellence
Medtronic operates with a global mindset, reaching patients in more than 150 countries. With its operational headquarters in the United States and legal headquarters in Ireland, the company effectively navigates diverse regulatory landscapes to maintain compliance while delivering high-quality medical devices. Approximately half of its revenue comes from international markets, underscoring its significance as a major player in the global medtech industry.
Partnerships and Industry Collaborations
Strategic partnerships further strengthen Medtronic’s market position. Collaborations with leading companies, such as those in imaging technology, enhance its product capabilities and help integrate novel hardware, software, and data-driven insights into clinical practice. These collaborations not only improve procedural outcomes but also provide a competitive edge in a field that continuously demands innovative therapeutic solutions.
Commitment to Quality and Clinical Expertise
Medtronic’s approach is deeply rooted in a commitment to clinical excellence and rigorous research. Every device is developed in accordance with strict quality controls and regulatory standards to ensure patient safety and efficacy. This clinical rigor, combined with an insatiable curiosity and diverse expertise, defines the company’s continued success. It is this commitment that has enabled Medtronic to remain at the forefront of treating over 70 critical health conditions through a continuously evolving product pipeline.
Industry Impact and Relevance
For investors and healthcare professionals, Medtronic represents more than just a manufacturer of medical devices. It embodies the transformative power of innovation in medicine by consistently addressing unmet clinical needs and improving patient outcomes. The company’s comprehensive portfolio and its integration of breakthrough technologies have set a benchmark for safety, reliability, and clinical performance in the competitive medical technology landscape.
Summary
In summary, Medtronic’s strength lies in its global scale, technological prowess, and ability to integrate complex therapeutic solutions seamlessly into clinical workflows. Its dedication to alleviating pain, restoring health, and extending life makes it a foundational pillar in modern healthcare, continuously evolving to meet the dynamic needs of patients and physicians alike.
Medtronic (NYSE: MDT) has received FDA approval for its Simplera Sync™ sensor for use with the MiniMed™ 780G system. The new disposable, all-in-one sensor requires no fingersticks with SmartGuard™ and features a simplified two-step insertion process.
The MiniMed™ 780G system's adaptive algorithm automatically adjusts glucose levels every 5 minutes using Meal Detection™ technology. Real-world data shows users achieve time in range above 70% when using optimal settings. The system works with the world's only 7-day infusion set, reducing injections by 96% compared to daily injections.
A launch of the Simplera Sync™ sensor in the U.S. is scheduled for fall 2025. Currently, the MiniMed™ 780G system operates with the Guardian™ 4 sensor.
Medtronic (NYSE: MDT) has announced compelling five-year outcomes from the Evolut Low Risk Trial for its Evolut™ TAVR system. The study, involving 1,414 patients (730 TAVR, 684 surgery), demonstrated that TAVR patients experienced comparable rates of all-cause mortality or disabling stroke (15.5%) versus surgery (16.4%) at five years.
Key findings showed a numerically lower rate of cardiovascular mortality in TAVR patients (7.2%) compared to surgery (9.3%), along with significantly larger effective orifice areas and lower mean gradients. The trial evaluated patients with severe aortic stenosis who had a predicted 30-day mortality risk below 3%.
The results, presented at the American College of Cardiology's Annual Scientific Session & Expo, support Evolut's supra-annular, self-expanding TAVR as a durable and effective alternative to surgery for severe aortic stenosis patients, regardless of surgical risk.
Medtronic (NYSE: MDT) has released two-year results from the SMART Trial, comparing their Evolut TAVR system with SAPIEN TAVR in patients with small aortic annulus. The study, presented at CRT 2025, is the largest international head-to-head comparative trial primarily enrolling women (87% of 716 patients) across 80+ sites worldwide.
The trial demonstrated comparable outcomes in mortality, disabling stroke, and heart failure hospitalization between both devices. However, Evolut TAVR showed superior valve performance with significantly less bioprosthetic valve dysfunction (BVD). Key findings include five times less prosthetic valve thrombosis and nine times less hemodynamic structural valve dysfunction compared to SAPIEN TAVR.
Medtronic (NYSE: MDT) has declared a quarterly cash dividend of $0.70 per ordinary share for the fourth quarter of fiscal year 2025. The dividend will be paid on April 11, 2025, to shareholders of record as of March 28, 2025.
This declaration aligns with the dividend increase announced in May 2024. As a member of the S&P 500 Dividend Aristocrats index, Medtronic has maintained a 47-year streak of consecutive annual dividend increases.
Headquartered in Galway, Ireland, Medtronic is a global healthcare technology company with 95,000+ employees across more than 150 countries. The company develops technologies and therapies for 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, surgical tools, and patient monitoring systems.
Medtronic (NYSE:MDT) has received FDA approval for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI), marking a significant advancement in Parkinson's disease treatment. The system represents the largest commercial launch of brain-computer interface technology to date.
The BrainSense™ Adaptive technology enhances Medtronic's Percept™ DBS neurostimulators by automatically adjusting therapy based on real-time brain activity, both in clinical settings and daily life. This personalized neuromodulation system has already served over 40,000 DBS patients worldwide with Percept™ devices.
The approval includes the BrainSense™ Electrode Identifier, which accelerates DBS programming settings by 85% compared to traditional methods. The technology is also available in Europe, with U.S. patient programming set to begin at select healthcare systems in the coming weeks, followed by nationwide availability in the coming months.
Medtronic (NYSE: MDT) reported Q3 FY25 financial results with revenue of $8.3 billion, up 2.5% as reported and 4.1% organic. GAAP diluted EPS was $1.01, increasing 2%, while non-GAAP diluted EPS reached $1.39, up 7%.
Key performance highlights include strong growth in Cardiac Ablation Solutions (low-20s growth) driven by pulsed field ablation products, and Diabetes revenue increasing 8.4% as reported. The company maintained its full-year guidance, expecting organic revenue growth of 4.75% to 5% and FY25 diluted non-GAAP EPS between $5.44 and $5.50.
The Cardiovascular Portfolio revenue grew 3.7% as reported, Neuroscience Portfolio increased 4.4%, while Medical Surgical Portfolio decreased 1.9%. The company highlighted significant improvements in both gross margin and operating margin, marking the ninth consecutive quarter of mid-single digit organic revenue growth.
Medtronic (NYSE: MDT) has announced it will release its third quarter fiscal year 2025 financial results on Tuesday, February 18, 2025. The earnings release will be available at 5:45 a.m. CST, followed by a video webcast at 7:00 a.m. CST to discuss the results for the quarter that ended January 24, 2025.
The company has also outlined its upcoming earnings release schedule, including Q4 FY2025 results on May 21, 2025, and quarterly results for FY2026 scheduled for August 19, 2025, November 18, 2025, February 17, 2026, and May 20, 2026.
Medtronic, headquartered in Galway, Ireland, is a global healthcare technology company with 95,000+ employees across 150+ countries. Their technologies treat 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems.
Inogen (NASDAQ: INGN) announced changes to its Board of Directors, effective January 2025. Mira Kirti Sahney has been appointed as a new board member, while Tom West will retire after serving since April 2023.
Sahney brings significant medical device industry experience, currently serving on Claria Medical's board and previously as President of Medtronic's Pelvic Health Operating Unit (2021-2024). Her experience includes roles as CEO of Hyalex Orthopaedics, leadership positions at Smith + Nephew, and co-founding Myomo. She holds multiple engineering degrees from University of Michigan and Stanford, plus an MBA from MIT.
In her new role, Sahney will join Inogen's Compliance Committee and the Nominating and Governance Committee. The appointment aims to strengthen Inogen's position as a global leader in respiratory care.
Medtronic (NYSE: MDT) has appointed Thierry Piéton as Chief Financial Officer, effective March 3, 2025. Piéton, who joins from Renault Group where he served as CFO since March 2022, will report to Chairman and CEO Geoff Martha and join the Executive Committee.
Under Piéton's leadership at Renault, the company achieved record operating margins and improved free cash flow, while executing portfolio management through acquisitions, divestitures, and innovative partnerships. His experience spans healthcare and regulated manufacturing industries, including roles at Nissan Motor, General Electric, GE Healthcare, and PricewaterhouseCoopers.
Gary Corona, who has been serving as interim CFO, will transition to Senior Vice President, Corporate Finance and remain on the Executive Committee. During Corona's interim tenure, Medtronic delivered revenue growth and exceeded EPS expectations in the first and second quarters.
Medtronic (NYSE: MDT) announced that the Centers for Medicare & Medicaid Services (CMS) is initiating a national coverage analysis (NCA) for renal denervation procedures for hypertension patients. This analysis will help develop a national Medicare coverage policy for the Symplicity™ Spyral renal denervation system, a minimally invasive treatment for high blood pressure.
The NCA was initiated in response to Medtronic's request to support Medicare beneficiary access to the system. This follows Medtronic's collaboration with CMS on the Transitional Coverage for Emerging Technologies (TCET) pathway for the FDA-approved breakthrough device. The expected completion date for the national coverage analysis is October 11, 2025. Until then, Symplicity blood pressure procedures will continue to be evaluated for coverage based on individual Medicare patient medical necessity.
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
What is the core business of Medtronic?
How does Medtronic generate revenue?
What markets does Medtronic serve?
How does Medtronic maintain its competitive edge?
What role do partnerships play in Medtronic's strategy?
How is Medtronic positioned in the medical technology industry?
What types of products does Medtronic offer?
What distinguishes Medtronic's approach to innovation?
How does Medtronic address patient safety?
What is Medtronic's global impact on healthcare?
